Mesoblast MESO
NASDAQ MESO
$17.32 +0.18 (+1.05%)
At close: Sep 4, 2026 · 4:00 PM EDT

Mesoblast (MESO) Total Non-Current Liabilities (2015 - 2026)

Mesoblast (MESO) posted Total Non-Current Liabilities of $79.6 million for Q4 2025, down 5.98% sequentially from $84.6 million in Q2 2025, and down 33.32% YoY from $119.3 million in Q4 2024.

Analysis

Mesoblast (MESO) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends

Mesoblast has reported Total Non-Current Liabilities for 11 years, with the latest figure at $79.6 million in Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 33.32% year-over-year to $79.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $79.6 million (down 33.32% YoY) and the FY2025 annual result came in at $84.6 million, down 26.78% from the prior year.
  • Total Non-Current Liabilities slipped to $79.6 million in Q4 2025 per MESO's latest filing, from $84.6 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $130.2 million in Q4 2023 and troughed at $66.6 million in Q1 2021.
  • A 5-year average of $102.5 million and a median of $112.9 million in 2022 frame the typical range for Total Non-Current Liabilities.
  • The sharpest annual moves came in 2021 and 2022: Total Non-Current Liabilities sank 34.2% in 2021, then jumped 68.61% in 2022.
  • Over 5 years, Total Non-Current Liabilities stood at $111.0 million in 2021, then grew by 2.26% to $113.5 million in 2022, then gained by 14.72% to $130.2 million in 2023, then declined by 8.36% to $119.3 million in 2024, then slumped by 33.32% to $79.6 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $79.6 million, $84.6 million, and $119.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 40.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 3.92 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 1.53 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1.88 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 4.20 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 9.32 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 1.17 Bn
10 Mesoblast 2.24 Bn 2.14 Bn - 123.56 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 123.56 Mn
Dec 31, 2025 79.55 Mn
Jun 30, 2025 84.62 Mn
Dec 31, 2024 10.58 Mn
Jun 30, 2024 115.56 Mn
Dec 31, 2023 17.07 Mn
Jun 30, 2023 16.61 Mn
Mar 31, 2023 8.17 Mn
Dec 31, 2022 9.00 Mn
Sep 30, 2022 9.85 Mn
Jun 30, 2022 12.52 Mn
Mar 31, 2022 13.18 Mn
Dec 31, 2021 110.98 Mn
Sep 30, 2021 69.17 Mn
Jun 30, 2021 17.02 Mn
Mar 31, 2021 17.82 Mn
Dec 31, 2020 19.44 Mn
Sep 30, 2020 20.72 Mn
Jun 30, 2020 27.56 Mn
Mar 31, 2020 28.11 Mn